Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia
Open Access
- 2 October 2002
- journal article
- Published by Springer Nature in Leukemia
- Vol. 16 (10) , 2159-2160
- https://doi.org/10.1038/sj.leu.2402729
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cellsBlood, 2000
- Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemiaLeukemia, 2000
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996